Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap

Simply Wall St.03-12

Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback. Enrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618130134?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-12 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618130134","market":"sg","top_or_hot":-1,"title":"Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap","media":"Simply Wall St.","content":"<div>\n<p>Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback. Enrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-phase-3-obesity-move-tests-vk2735-valuat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-phase-3-obesity-move-tests-vk2735-valuat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback. Enrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-phase-3-obesity-move-tests-vk2735-valuat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-phase-3-obesity-move-tests-vk2735-valuat","article_id":"2618130134","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vktx/viking-therapeutics/news/viking-therapeutics-phase-3-obesity-move-tests-vk2735-valuat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618130134","pubTimestamp":1773325429,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback.\nEnrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 and VANQUISH-2, is reported to be nearly complete.\nThe company has also started a new maintenance and transition study for the oral version of VK2735, with readouts expected later this year.\n\nViking Therapeutics focuses on metabolic and endocrine disorders, and VK2735 sits at the center of its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4599":"减肥药","VKTX":"Viking Therapeutics, Inc."},"translate_title":"Viking Therapeutics 3期肥胖举措测试VK2735估值差距","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1.5},"content_text":"Viking Therapeutics (NasdaqCM:VKTX) has advanced its obesity drug candidate VK2735 into Phase 3 development following FDA feedback. Enrollment for the pivotal subcutaneous Phase 3 trials, VANQUISH-1 and VANQUISH-2, is reported to be nearly complete. The company has also started a new maintenance and transition study for the oral version of VK2735, with readouts expected later this year.  Viking Therapeutics focuses on metabolic and endocrine disorders, and VK2735 sits at the center of its obesity pipeline. With multiple large pharma companies also working on weight loss drugs, investors are watching how smaller specialists such as Viking position their programs. The shift in healthcare spending toward obesity treatments has turned late stage clinical progress into a key reference point for many shareholders. For investors, these new trials help clarify what the potential regulatory path for VK2735 might look like, even though outcomes remain uncertain. The combination of subcutaneous Phase 3 studies and an oral maintenance trial provides additional data points that could influence future partnership discussions, capital needs, and any eventual commercialization strategy if approvals are pursued. Stay updated on the most important news stories for Viking Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Viking Therapeutics. NasdaqCM:VKTX Earnings & Revenue Growth as at Mar 2026 1 thing going right for Viking Therapeutics that this headline doesn't cover. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$35.76 versus a consensus target of about US$92.72, the price sits roughly 61% below analyst expectations. ✅ Simply Wall St Valuation: Simply Wall St currently assesses Viking as trading about 87.2% below its estimated fair value. ✅ Recent Momentum: The stock has returned about 22.0% over the last 30 days.  There is only one way to know the right time to buy, sell or hold Viking Therapeutics. Head to Simply Wall St's\ncompany report for the latest analysis of Viking Therapeutics's Fair Value. Key Considerations  📊 Advancing VK2735 into Phase 3 with enrollment nearly complete makes clinical results a central driver of how investors may reassess Viking at US$35.76. 📊 Keep an eye on Phase 3 VK2735 obesity readouts, oral maintenance study data later this year, and any updates to the US$92.72 analyst price target range of US$35 to US$125. ⚠️ Viking remains a clinical stage company with US$0 revenue and ongoing losses, so any setback in VK2735 could weigh heavily on the current valuation case.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Viking Therapeutics analysis. Alternatively, you can check out the\ncommunity page for Viking Therapeutics to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618130134","isCrawlerRequest":true}